- Home
- NTIC vs CNTX Comparison
NTIC vs CNTX Comparison
Compare NTIC & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIC
- CNTX
- Stock Information
- Founded
- NTIC 1970
- CNTX 2015
- Country
- NTIC United States
- CNTX United States
- Employees
- NTIC N/A
- CNTX N/A
- Industry
- NTIC Industrial Specialties
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- NTIC Industrials
- CNTX Health Care
- Exchange
- NTIC Nasdaq
- CNTX Nasdaq
- Market Cap
- NTIC 71.5M
- CNTX 78.0M
- IPO Year
- NTIC N/A
- CNTX 2021
- Fundamental
- Price
- NTIC $8.46
- CNTX $0.74
- Analyst Decision
- NTIC Buy
- CNTX Strong Buy
- Analyst Count
- NTIC 1
- CNTX 5
- Target Price
- NTIC $20.00
- CNTX $5.50
- AVG Volume (30 Days)
- NTIC 82.7K
- CNTX 163.6K
- Earning Date
- NTIC 07-10-2025
- CNTX 08-06-2025
- Dividend Yield
- NTIC 0.48%
- CNTX N/A
- EPS Growth
- NTIC N/A
- CNTX N/A
- EPS
- NTIC 0.31
- CNTX N/A
- Revenue
- NTIC $85,268,129.00
- CNTX N/A
- Revenue This Year
- NTIC $2.05
- CNTX N/A
- Revenue Next Year
- NTIC $4.70
- CNTX N/A
- P/E Ratio
- NTIC $26.90
- CNTX N/A
- Revenue Growth
- NTIC 3.46
- CNTX N/A
- 52 Week Low
- NTIC $6.75
- CNTX $0.49
- 52 Week High
- NTIC $15.09
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- NTIC 60.52
- CNTX 64.15
- Support Level
- NTIC $7.91
- CNTX $0.62
- Resistance Level
- NTIC $8.97
- CNTX $0.67
- Average True Range (ATR)
- NTIC 0.51
- CNTX 0.05
- MACD
- NTIC 0.09
- CNTX 0.02
- Stochastic Oscillator
- NTIC 74.38
- CNTX 71.12
About NTIC Northern Technologies International Corporation
Northern Technologies International Corp, or NTIC is a United States-based firm that develops and markets environmentally beneficial products and services world-wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.